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Abstract: Atypia/follicular lesion of undetermined significance (AUS/
FLUS) is a new category in the Bethesda System for Reporting Thyroid
Cytopathology (BSRTC) for which repeat fine-needle aspiration
cytology (FNAC) is recommended. The aim of this study was to identify
specific ultrasonography and clinical predictors of malignancy in a
subset of thyroid nodules associated with cytology diagnoses of AUS/
FLUS.
Between January 2011 and December 2102, 5440 patients under-
went thyroid surgery at our institution. Of these, 213 patients were
diagnosed AUS/FLUS at the preoperative cytopathology diagnosis. The
frequency of FNAC and ultrasonography images was compared
between patients with cancerous and benign tumors based on their final
pathology.
Of the 213 patients, 158 (74.2%) were diagnosed with thyroid
carcinoma in their final pathology reports. In univariate and multivariate
analyses, the frequency of FNAC was not significantly correlated with
the cancer diagnosis. Hypoechogenicity (odds ratio 2.521, P¼ 0.007)
and microcalcification (odds ratio 3.247, P¼ 0.005) were statistically
correlated with cancer risk.
Although AUS/FLUS in cytopathology is recommended for repeat-
ing FNAC in BSRTC, we proposed that thyroid nodules with ultra-
sonography findings that suggest the possibility of cancer should
undergo thyroidectomy with diagnostic intent.
(Medicine 94(51):e2183)
Abbreviations: AUS/FLUS = atypia or follicular lesion of
undetermined significance, BSRTC = Bethesda system for, Hojin Chang, MD m, MD,
FACS, and Cheong Soo Park, MD, PhD, FACS
INTRODUCTION
T hyroid cancer is the first leading cancer accountingfor 17.8% of all new cancers diagnosed in the Korean
population.1
Cervical ultrasonography (US) is mandatory before
surgery for thyroid cancer and is recommended for thyroid
nodule evaluation. Fine-needle aspiration cytology (FNAC)
under ultrasonography guidance represents the critical initial
diagnostic test used to evaluate thyroid nodules and stratify the
risk of malignancy. FNAC plays a key role in disease manage-
ment.2,3
Traditionally, cytological interpretations categorize the
specimen into 1 of the 4 diagnostic categories: negative,
positive, nondiagnostic, and indeterminate.
As thyroid nodules are evaluated and treated, the first
question the cytopathologist encounters is regarding specimen
adequacy. If the cytopathologist encounters cellular paucity,
most diagnose the nodules as nondiagnostic. The second ques-
tion that clinicians encounter is indeterminate diagnoses. Inde-
terminate cytological diagnoses occur in follicular patterned
thyroid lesions owing to overlapping cytomorphologic charac-
teristics of benign and malignant lesions.4 The distinction
between benign and malignant thyroid nodules has remained
challenging for clinicians.
To improve the classification, a revised classification
system for reporting thyroid FNAC was proposed at the
National Cancer Institute State of Science conference in
2007. This led to the Bethesda System for Reporting Thyroid
Cytopathology (BSRTC), which was adopted in 2009 and
comprised the following 6 classifications: unsatisfactory/non-
diagnostic (category I), benign (category II), atypia or follicular
lesion of undetermined significance (AUS/FLUS) (category
III), follicular neoplasm/suspicious for follicular neoplasm
(category IV), suspicious for malignancy (categoryV), and
positive for malignancy (category VI) (Table 1).5
The traditional indeterminate group was further divided
into the AUS/FLUS (category III) and follicular neoplasm
(category IV) categories in BSRTC
AUS/FLUS is a new category in the BSRTC, with malig-
nancy rates of 5% and 15%, for which repeat FNAC is
recommended.5 According to the BSRTC, the reported rates
of AUS/FLUS have been between 3% and 18% of thyroid
FNAC. Furthermore, the frequency of AUS/FLUS diagnosis
should be 7% or less of all thyroid FNAC.6–8
As per the synopsis of the NCISSC, patients with AUS/
FLUS FNAC should undergo a second FNAC after 3 monthslations and/or ultrasound findings.5,9–11
AC before 3 months is hypothesized to
f reparative atypia of follicular cells,
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TABLE 1. The Bethesda System for Reporting Thyroid Cytopathology: Implied Risk of Malignancy a Recommended Clinical
Management5
Diagnostic Category Risk of Malignancy (%) Usual Management
Nondiagnostic or unsatisfactory 1–4 Repeat FNAC
Benign 0–3 Clinical follow-up
Atypia of undetermined significance or
follicular lesion of undetermined
significance
5–15 Repeat FNAC
Follicular neoplasm or suspicious for
follicular neoplasm
15–30 Surgical lobectomy
Suspicious for malignancy 60–75 Near-total thyroidectomy or surgical
lobectomy
7–9
Lee et al Medicine  Volume 94, Number 51, December 2015increasing the potential for false-positive diagnoses of malig-
nancy (Table 1).12
Someconcerns and confusionwere encounteredwhenadapt-
ing theAUSdiagnosis according to theBSRTC.First,AUS/FLUS
is a heterogeneous category that contain follicular cells and/or
nuclear atypia that exceed benign changes, but the changes are not
enough to justify classification into any of the other diagnostic
categories.5,12,13 Thus, it has been suggested that AUS could be
further subclassified into more distinct subtypes that consulting a
distinct consequence for the risk of malignancy.13–16
Second, although patients with a repeated diagnosis of
AUS/FLUS require surgical intervention,6 the benefit for
patients between repeated FNAC and surgical intervention is
not yet clearly established.
The aim of this study was to identify specific ultrasono-
graphy and clinical predictors of malignancy in a subset of
thyroid nodules associated with cytology diagnoses of AUS/
FLUS at our institution and optimal surgical treatment of
these nodules.
MATERIALS AND METHODS
Patient Cohort and Selection
This study was approved by the Institutional Review Board
of Gangnam Severance Hospital, Yonsei University College of
Medicine, and was conducted according to the principles of the
Helsinki Declaration (IRB No.3-2013-0246).
Between January 2011 and December 2012, a total of 8244
FNAC were performed at the Thyroid Cancer Center, Gangnam
Severance Hospital, Yonsei University College of Medicine,
Seoul, Korea. Of these, 757 FNACs (9.2%) were interpreted as
AUS/FLUS in BSRTC. Patients who underwent thyroid surgery
for recurrent thyroid cancer were excluded.
Patients with typical features for thyroid cancer on ultra-
sonography imaging were recommended thyroidectomy, and
patients with controversial ultrasonography findings who
wanted repeated FNAC received repeated FNAC. If patients
had controversial ultrasonography findings repeatedly, they
were recommended for the same process.
Finally, of the 757 cases of AUS/FLUS, 284 cases (37.5%)
that were reported as suspicious for follicular neoplasm
(category IV), suspicious for malignancy (categoryV), or
Malignant 9
FNAC¼fine-needle aspiration cytology.malignant (category IV) underwent thyroidectomy, 213 cases
(28.1%) underwent thyroidectomy after a diagnosis of AUS/
FLUS, and 260 cases (34.4%) were closely observed.
2 | www.md-journal.comDuring the same period, a total of 5440 patients underwent
thyroid surgery. Of these, 213 (3.9%) patients were AUS/FLUS
at preoperative cytopathology diagnosis.
After identification of the enrolled patients, medical
records including patient demographics, subsequent clinical
outcomes, imaging studies such as ultrasonography, FNAC
results, and surgical pathology results, were retrospectively
reviewed. The surgical extent for thyroid cancer was decided
by the American Thyroid Association (ATA) and Korean Thyr-
oid Association (KTA) guidelines.2,3
Classification of Ultrasonography Findings of
Nodules With AUS/FLUS
US features were described based on the ‘‘Guidelines for
Thyroid US’’ by the Thyroid Study Group, Korean Society of
Head and Neck Radiology.17
US findings of the thyroid nodules were evaluated for the
following categories: shape, margins, echogenicity, and calcifi-
cation. Nodule shape was described as oval-to-round, taller than
wide or irregular. The margin was described as well defined, ill
defined, or speculated. The presence of calcification was
described as none, microcalcification (<1mm), or macrocalci-
fication (1mm). The echogenicity of the nodule was described
as hyper-, iso-, or hypoechogenic compared with the thyroid
gland or as markedly hypoechogenic compared with the adjacent
strap muscle. US criteria for malignant modules were taller-than-
wide, speculated margin, marked hypoechogenicity, and the
presence of micro- or macrocalcifications.17
FNAC and Cytology Interpretation
FNACwere performed under ultrasound guidance using 3 to
4 passeswith 22-gauge needles. Syringeswith FNACwere rinsed
in a methanol–water solution (ThinPrep CytoLyt, Hologic).
A board-certified cytopathologist made cytology interpret-
ations and classifications based on the BSRTC.5 The transition
to BSRTC took place in December 2009 at our institution. The
BSRTC categories were comprised of the following: unsatis-
factory/nondiagnostic, benign, AUS/FLUS, follicular neo-
plasm/suspicious for follicular neoplasm, suspicious for
malignancy, and positive for malignancy (Table 1).
9 Near-total thyroidectomyStatistical Analyses
Student t tests were used for univariate analyses when
comparing selected variables. Pearson’s chi squared tests were
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 2. Univariate and Multivariate Analyses of Times of FNAC and Ultrasonographic Features
Univariate Analyses Multivariate Analyses
Variables Benign (n¼ 55) Malignant (n¼ 158) P Value Odds Ratio (95% CI) P Value
Times of FNAC 0.573 1.139 (0.443–2.932) 0.787
1 (n¼ 179) 48 (26.8%) 131 (73.2%)
2 (n¼ 24) 4 (16.7%) 20 (83.3%)
3 (n¼ 10) 3 (30.0%) 7 (70.0%)
Ultrasonography features
Taller than wide 0 (0.0%) 20 (12.7%) 0.003 – 0.998
Ill-defined margin 21 (38.2%) 92 (58.2%) 0.012 1.482 (0.746–2.943) 0.262
Hypoechogenecity 29 (52.7%) 120 (75.9%) 0.002 2.521 (1.393–5.431) 0.007
Microcalcification 9 (16.4%) 67 (42.4%) 0.001 3.247 (1.533–8.027) 0.005
Medicine  Volume 94, Number 51, December 2015 Thyroidectomy in Patients With AUS/FLUSused to analyze categorical and nonparametric data. Multiple
logistic regression analyses with a forward stepwise variable
selection procedure were used to select significant variables and
identify independent predictors of malignancy. A P value of
<0.05 was considered statistically significant.
RESULTS
There were 757 AUS/FLUS on preoperative FNAC. Of
these, 213 cases (28.1%) underwent thyroidectomy under the
preoperative diagnosis of AUS/FLUS. Of the 213 patients, 158
(74.2%) were diagnosed with thyroid carcinoma at the final
pathology reports.
In univariate analyses, repeated times of FNAC did not
correlate with cancer risk. Patients with repeated FNAC (>2
times) were similar to patients with single FNAC (Table 2,
P¼ 0.573).
Based on US findings, thyroid nodules that were confirmed
as carcinoma on the final pathology reports showed signifi-
cantly more malignant features than benign confirmed nodules:
taller than wide (12.7% vs 0%, P¼ 0.003), ill-defined margins
(58.2% vs 38.2%, P¼ 0.010), hypoechogenicity (75.9% vs
52.7%, P¼ 0.001), and microcalcification (17.1% vs 12.7%,
P¼ 0.001) (Table 2).
In multivariate analyses, the frequency of FNAC was not
significantly correlated with cancer diagnosis. From the US
findings, hypoechogenicity (odds ratio 2.521, P¼ 0.007) and
microcalcification (odds ratio 3.247, P¼ 0.005) were signifi-
CI¼ confidence interval, FNAC¼fine-needle aspiration cytology.cantly correlated with cancer risk (Table 2).
Scoring using variables that were statistically significant in
Table 2 (taller than wide, ill-defined margin, hypoechogenicity,
TABLE 3. Scoring Using Variables that Have Statistical Significan
Number of Variables Benign (n¼ 55) Malignant (n¼ 1
0 16 (51.6%) 15 (48.4%)
1 22 (36.1%) 39 (63.9%)
2 14 (19.2%) 59 (80.8%)
3 3 (7.3%) 38 (92.7%)
4 0 (0%) 7 (100%)
Variables: taller than wide, ill-defined margin, hypoechogenicity, and m
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.and microcalcification) showed that as the number of malignant
US characteristics of cancer increased, the possibility of cancer
is increased (Pearson’s correlation coefficient¼ 0.990,
P< 0.001) (Table 3).
DISCUSSION
FNAC has an essential role in the evaluation of thyroid
nodules. Traditionally, the cytological interpretation categor-
izes the specimen into 1 of the 4 diagnostic categories: negative,
positive, nondiagnostic, and indeterminate.
However, some thyroid FNACs are not easily classified
into the benign, suspicious, or malignant categories. Indetermi-
nate diagnoses have been used to represent follicular patterned
thyroid lesions due to the overlapping cytomorphologic charac-
teristics of benign and malignant lesions.
After the National Cancer Institute Thyroid Fine Needle
Aspiration State of the Science Conference took place in
October 2007, the Bethesda System for Reporting Thyroid
Cytopathology (BSRTC) was proposed. BSRTC was adopted
worldwide in 2009 and our institution adopted in 2009.
In BSRTC, some thyroid FNACs that are not easily
classified into benign or malignant were reported as ‘‘Atypia
of Undetermined Significance (AUS)’’ or ‘‘Follicular Lesion of
Undetermined Significance (FLUS)’’ in the Bethesda System
for Reporting Thyroid Cytology. AUS/FLUS are included in the
indeterminate diagnoses.
The risk of malignancy for all AUS/FLUS cases including
those patients with benign results at follow-up and who did not
undergo surgery is presumably 5% to 15%.6 The malignancy
rates in recently published studies using the BSRTC show a
ce in Table 2
58) Pearson’s Correlation Coefficient (r) P Value
0.990 <0.001
icrocalcification.
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BSRTC, thyroidectomy with diagnostic intent may be recom-wide range of 6% to 48% in resected cases and 5% to 27% in all
cases.8,18–20
In the present study, the overall neoplastic rate for patients
with at least 1 AUS/FLUS diagnosis was 9.2% (757 out of 8244)
for all cases and 28.1% (213 out of 757) for cases with
surgical intervention.
AUS/FLUS in the Bethesda System has been a difficult
and challenging category for pathologists and clinicians,
because the risk of malignancy is lower and likely closer to
5% to 15%.
For pathologists, the AUS/FLUS category should be used
as a last resort and limited to7% or less of all thyroid FNACs.
The risk of malignancy for an AUS/FLUS nodule is difficult to
ascertain because only a minority of cases in this category have
surgical intervention. Those that are surgically resected
represent a select population of patients with repeated AUS/
FLUS results or patients with worrisome clinical or US find-
ings.21
For clinicians, the classification of AUS/FLUS thyroid
FNAC biopsy specimens can result in difficulty in terms of
clinical management and follow-up. Benign categorization is
followed clinically, and follicular neoplasm/suspicious for
malignancy categories are subject to surgical intervention.
The AUS/FLUS category is less clearly clinically defined,
and management varies from repeat FNAC (after 3–6 months)
to surgical evaluation. Once AUS/FLUS has been diagnosed for
a thyroid FNAC specimen, the clinician must decide on how to
proceed and manage the patient.
The recommended approach for initial AUS/FLUS is to
repeat FNAC (Table 1).5 A repeat FNAC usually results in a
more definitive diagnosis, and only 20% to 25% of nodules
repeatedly receive a diagnosis of AUS/FLUS.8,22 However,
there are no recommended guidelines for repeated AUS/FLUS.
Some patients are recommended for repeat FNAC whereas
others are recommended for diagnostic surgical resection.
Repeat FNACwere more prevalent than surgical resection.
Repeat FNAC to follow up AUS/FLUS results is more cost
effective than diagnostic surgical resection.23 Moreover, clin-
icians cannot easily recommend surgical resection because
clinicians and patients are not certain of carcinoma.
Increased efforts have focused on solving the limitations of
AUS/FLUS. Subclassification of AUS/FLUS, molecular tests
such as evaluation of BRAF mutation, and core-needle biopsies
have been recommended and performed.13,24 However, none of
these methods solve these limitations.
US findings are the most important findings for clinicians.
US findings that predict malignancy may be valid due to their
high specificity and positive predictive value. In the present
study, we examined some US features to evaluate their associ-
ated impacts on malignancy rates in patients with a preoperative
cytological diagnosis of AUS/FLUS and subsequent surgical
intervention.
Some US features, including taller than wide, ill-defined
margin, hypoechogenicity, and microcalcification, were suffi-
cient to identify malignant nodules in univariate analyses.
Hypoechogenicity (odds ratio 2.521, P¼ 0.007) and microcal-
cification (odds ratio 3.247, P¼ 0.005) were significantly cor-
related with cancer (Table 2). Specifically, as the number of
malignant US characteristics increased, the possibility of cancer
increased (Pearson’s correlation coefficient¼ 0.990, P< 0.001)
Lee et al(Table 3). We also investigated the correlation between FNAC
times and cancer diagnosis; however, the malignancy rate did
not increase according to FNAC times.
4 | www.md-journal.comCONCLUSIONS
Repeated AUS/FLUS results in preoperative FNAC are
challenging for pathologists and clinicians. If indications for
thyroidectomy, regardless of AUS/FLUS results, were estab-
lished, repeat biopsies do not appear necessary. Although AUS/
FLUS in cytopathology is recommended for repeating FNAC in
Medicine  Volume 94, Number 51, December 2015mended for thyroid nodules with US findings that suggest the
possibility of cancer.
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